Kala Bio KALA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Kala Bio (KALA) Business Model and Operations Summary
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Key Insights
Kala Bio (KALA) Core Market Data and Business Metrics
Latest Closing Price
$4.77Market Cap
$29.85 MillionPrice-Earnings Ratio
-0.39Total Outstanding Shares
6.45 Million SharesTotal Employees
43Dividend
No dividendIPO Date
July 20, 2017SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
1167 Massachusetts Avenue, Arlington, MA, 02476
Historical Stock Splits
If you bought 49.95 shares of KALA before August 26, 2022, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| October 21, 2022 | 1-for-50 (Reverse Split) |
| August 26, 2022 | 1.001-for-1 |
Short Interest
Short Interest
This information is bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Average Daily Volume: The average number of shares traded per day over the specified period.
Days to Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Short Interest | Bi-Weekly Change (%) | Settlement Date | Days to Cover |
|---|---|---|---|
| 274,816 Shares | -3.28% | 3/14/2025 | 12.51 |
| 284,149 Shares | -5.50% | 2/28/2025 | 5.74 |
| 300,692 Shares | +88.76% | 2/14/2025 | 2.35 |
| 159,301 Shares | +971.80% | 1/31/2025 | 2.13 |
| 14,863 Shares | -41.83% | 1/15/2025 | 1 |
| 25,551 Shares | +19.06% | 12/31/2024 | 1.05 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-6.86 Million |
| Net Cash Flow, Continuing | $-6.86 Million |
| Net Cash Flow From Operating Activities, Continuing | $-32.48 Million |
| Net Cash Flow From Financing Activities, Continuing | $25.77 Million |
| Net Cash Flow From Financing Activities | $25.77 Million |
| Net Cash Flow From Investing Activities, Continuing | $-146,000 |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $-38.96 Million |
| Revenues | $0 |
| Diluted Average Shares | $10.57 Million |
| Basic Average Shares | $10.57 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss | $-38.96 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-38.96 Million |
| Other Comprehensive Income/Loss | $-18.53 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-38.96 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Wages | $775,000 |
| Other Current Liabilities | $22.38 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Current Liabilities | $23.87 Million |
| Liabilities | $47.22 Million |
| Equity | $6.86 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||